Apolipoprotein(a) phenotypes are reliable biomarkers for familial aggregation of coronary heart disease

  • Authors:
    • Emmanouil Peros
    • Diego Geroldi
    • Angela D'Angelo
    • Colomba Falcone
    • Lorenza Montagna
    • Maria Carabela
    • Enzo Emanuele
  • View Affiliations

  • Published online on: February 1, 2004     https://doi.org/10.3892/ijmm.13.2.243
  • Pages: 243-247
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Lipoprotein(a) [Lp(a)] is an atherogenic and prothrombotic molecule formed by the covalent binding of the highly polymorphic apolipoprotein(a) [apo(a)] to apoprotein B-100 of LDL. High Lp(a) concentrations are a recognized genetic risk factor for coronary heart disease (CHD) and have been shown to be related with a familial clustering of ischemic cardiac events. Nevertheless, the association between apolipoprotein(a) isoforms and a positive familial history of CHD has received far less attention. In this report, we explored the distribution of apo(a) phenotypes in 127 CHD subjects with a family history of coronary events and in 92 CHD patients without such a history. Twenty-two apo(a) isoforms were detected by a high-resolution immunoblotting method. In univariate analysis, the percentage of subjects with at least one small sized apo(a) isoform was significantly higher in CHD patients with a positive family history than in those without (P<0.01). Multivariate analysis showed that apo(a) isoforms of low molecular weight were the best predictors of familial aggregation of cardiac ischemia. We conclude that apo(a) size polymorphism is strongly associated with a familial history of CHD and is more efficient than Lp(a) plasma concentrations in predicting the familial clustering of coronary disease. When detected by high-resolution techniques, apo(a) phenotypes are objective laboratory markers that can substitute for a knowledge of a positive family history of CHD and should be used, together with Lp(a) levels, to better assess the familial predisposition to coronary events.

Related Articles

Journal Cover

February 2004
Volume 13 Issue 2

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Peros E, Geroldi D, D'Angelo A, Falcone C, Montagna L, Carabela M and Emanuele E: Apolipoprotein(a) phenotypes are reliable biomarkers for familial aggregation of coronary heart disease. Int J Mol Med 13: 243-247, 2004.
APA
Peros, E., Geroldi, D., D'Angelo, A., Falcone, C., Montagna, L., Carabela, M., & Emanuele, E. (2004). Apolipoprotein(a) phenotypes are reliable biomarkers for familial aggregation of coronary heart disease. International Journal of Molecular Medicine, 13, 243-247. https://doi.org/10.3892/ijmm.13.2.243
MLA
Peros, E., Geroldi, D., D'Angelo, A., Falcone, C., Montagna, L., Carabela, M., Emanuele, E."Apolipoprotein(a) phenotypes are reliable biomarkers for familial aggregation of coronary heart disease". International Journal of Molecular Medicine 13.2 (2004): 243-247.
Chicago
Peros, E., Geroldi, D., D'Angelo, A., Falcone, C., Montagna, L., Carabela, M., Emanuele, E."Apolipoprotein(a) phenotypes are reliable biomarkers for familial aggregation of coronary heart disease". International Journal of Molecular Medicine 13, no. 2 (2004): 243-247. https://doi.org/10.3892/ijmm.13.2.243